Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Diane 35 cyproterone/ethinylestradiol regulatory update

EMA's Pharmacovigilance Risk Assessment Committee (PRAC) concluded that the benefits of Bayer's Diane 35 cyproterone/ethinylestradiol and its generic versions

Read the full 196 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE